Possible strategies for antimetastastic therapy.
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001777:Blood Coagulation; D001792:Blood Platelets / Q000473:pathology / Q000502:physiology; D001808:Blood Vessels / Q000473:pathology; D002448:Cell Adhesion; D002450:Cell Communication; D002478:Cells, Cultured; D006224:Cricetinae; D003546:Cysteine Endopeptidases; D004195:Disease Models, Animal; D010450:Endopeptidases / Q000302:isolation & purification / Q000494:pharmacology; D011464:Epoprostenol / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D007694:Killer Cells, Natural / Q000276:immunology; D008175:Lung Neoplasms / Q000032:analysis / Q000556:secondary; D008545:Melanoma / Q000473:pathology; D051379:Mice; D009362:Neoplasm Metastasis; D009363:Neoplasm Proteins; D009368:Neoplasm Transplantation; D009374:Neoplasms, Experimental / Q000032:analysis; D010974:Platelet Aggregation / Q000187:drug effects*; D015230:Prostaglandin D2; D011457:Prostaglandins D / Q000627:therapeutic use; D011817:Rabbits; D051381:Rats; D013921:Thrombocytopenia / Q000503:physiopathology; D013930:Thromboxane-A Synthase / Q000037:antagonists & inhibitors
D000970:Antineoplastic Agents; D009363:Neoplasm Proteins; D011457:Prostaglandins D; D011464:Epoprostenol; D010450:Endopeptidases; D003546:Cysteine Endopeptidases; C030910:cancer procoagulant; D013930:Thromboxane-A Synthase; D015230:Prostaglandin D2